Core Points - The company is holding its annual general meeting to discuss various proposals, including financial reports and governance changes [1][3][19] - The meeting will take place on June 26, 2025, at 14:00 in Yantai, China, with both on-site and online voting options available [4][5][6] Meeting Procedures - Attendees must register and verify their identity to participate in the meeting [1][2] - Shareholders have the right to speak, ask questions, and vote on proposals, but must adhere to the meeting's agenda and time limits [2][3] - The meeting will be conducted in an orderly manner, with the chairman having the authority to manage discussions and responses to questions [2][3][4] Agenda Items - The meeting will review and vote on several key proposals, including: - The 2024 annual board report [8][10] - The 2024 annual supervisory report [10] - The 2024 financial settlement report, which has been audited and approved [11] - The 2024 annual report and its summary [12] - A proposal for profit distribution, indicating no distribution for 2024 [13] - The reappointment of accounting firms for 2025 [13] - Confirmation of director and supervisor remuneration for 2024 [14][18] - A proposal for general authorization to issue new shares [15][16] - Changes to the company's registered capital and governance structure, including the abolition of the supervisory board [17][21] - Amendments to the company's articles of association and meeting rules [19][20][22] Financial Performance - The company reported significant sales growth, particularly from its products, with a revenue of 1.699 billion yuan from one of its drugs [24] - The company is focused on maintaining high R&D investment while reducing net losses compared to previous years [24]